AMEND are delighted to be providing administrative and organisational support to the convenors of a new and exciting RET Research Collaborative Network, called RET@CRICK, whose inaugural meeting will be held at The Francis Crick Institute in London on 10th June, 2019.  Germline (in DNA) and somatic (in tissue) RET gene mutations are responsible for a range of rare diseases, including multiple endocrine neoplasia type 2 (MEN2), familial and sporadic medullary thyroid cancer (MTC) and phaeochromocytomas, and Hirschsprung’s disease (HD).

The RET Research Collaborative Network will facilitate the exchange of ideas and collaborative initiatives leading to innovative projects and grant applications, and will coordinate research with ongoing clinical care to encourage recruitment into laboratory based projects and clinical trials.  The RET@CRICK meeting is envisaged as a stepping stone towards this goal.

The one-day event will bring together scientific and clinical leaders in their field as well as junior doctors and researchers who can present their research in a poster format.  The day will consist of four 90-minute sessions, each comprised of a triad of Scientific, Clinical and New Research talks, followed by an open forum discussion and networking breaks.  Presentations will cover important aspects of RET-related diseases including MEN2, MTC, Hirschsprung’s disease, animal models and RET targeting in oncology, as well as the role of RET in development and physiology.  RET@CRICK is an excellent opportunity for both scientists and clinicians to test new ideas, find potential collaborators and get engaged in world class translational research.

For more information and to book a place, please click here.